Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bremelanotide with Tirzepatide for Obesity
NCT06565611Phase 2Active, not recruiting
- Sponsor
- Palatin Technologies, Inc.
- Start
- Aug 2024
- Primary completion
- Feb 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bremelanotide in obesity, sponsored by Palatin Technologies, Inc.. Started Aug 2024; status: active, not recruiting.
02
Drugs
bremelanotide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06565611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06565611.